Aldesleukin (Proleukin)

Aetna covers intravenous aldesleukin (Proleukin) for metastatic melanoma (including FDA‑approved adult metastatic melanoma and high‑dose single‑agent subsequent therapy for cutaneous metastatic/unresectable disease), metastatic clear‑cell renal cell carcinoma, chronic GVHD as adjunct therapy with corticosteroids after first‑line failure, and neuroblastoma. All other indications are experimental/investigational (including subcutaneous IL‑2 except intralesional IL‑2 for melanoma, IL‑2 receptor antagonist induction in renal transplant, and pleural sIL‑2R testing), and intravenous Proleukin must be administered in a hospital under a physician experienced in anticancer agents.

"Medical records documenting absence of contraindicated prior toxicities for retreatment (e."

Sign up to see full coverage criteria, indications, and limitations.